Sapience Therapeutics, Inc.

CRC is becoming more deadly for younger patients. In the late 1990s, CRC was the fourth-leading cause of cancer death in both men and women younger than 50 years old. In this age group, CRC is now the top cause of cancer deaths in men and the second-leading cause of cancer deaths in women. At Sapience Therapeutics, Inc., we continue to be committed to advancing therapies for patients with difficult-to-treat cancers. Our first-in-class β-catenin antagonist, ST316, selectively targets the Wnt pathway, which drives more than 80% of CRCs. Discover how Sapience Therapeutics is advancing the fight against CRC with ST316, and learn more about our Phase 2 Dose Expansion Study here: https://lnkd.in/gpuJBTrn     #FightColorectalCancer #ColorectalCancer

Colorectal cancer incidence is on the rise in younger adults. In 1995, the proportion of newly diagnosed patients younger than age 55 was 11%. In 2019, this proportion grew to 20% – nearly doubling. At Sapience Therapeutics, Inc., we are committed to advancing therapies for this devastating disease. Our first-in-class β-catenin antagonist, ST316, selectively targets the Wnt pathway, which drives more than 80% of CRCs. We are currently enrolling CRC patients in a Phase 2 Dose Expansion Study across lines of treatment in combination with standard of care. Learn more here: https://lnkd.in/gpuJBTrn     #FightColorectalCancer #ColorectalCancer

Colorectal cancer (CRC) affects millions of Americans every year. With more than 80% of CRCs estimated to be driven by the Wnt/β-catenin signaling pathway, Sapience Therapeutics, Inc. is proud to advance ST316 - a first-in-class Wnt/β-catenin inhibitor with selective targeting capabilities.   We are currently enrolling CRC patients in a Phase 2 Dose Expansion Study across lines of treatment in combination with standard of care. Discover how Sapience Therapeutics is advancing the fight against CRC with ST316: https://lnkd.in/gpuJBTrn     #FightColorectalCancer #ColorectalCancer

The Sapience Therapeutics, Inc. team is getting ready for #SITC2024! Please join us for presentations on both ST101 and ST316. Jim Rotolo, Ph.D., our SVP of Research and Translational Sciences, will deliver an oral presentation on ST101 clinical data from our GBM window of opportunity study. Claudio Scuoppo, Ph.D., Principal Scientist, will present a preclinical poster on ST316, our peptide antagonist of β-catenin. We hope to see you next month in Houston! Learn more here: https://lnkd.in/gWkpyv2t #Biotech #Oncology #DrugDevelopment

Next week, we are looking forward to participating at the 4th Annual Needham & Company Private Biotech Company Virtual 1x1 Forum and engaging with investors in one-on-one meetings. Learn more here: https://lnkd.in/gcNF-J6c #Needham24 #Biotech #Oncology #DrugDevelopment

Colorectal cancer (CRC) is the second most common cause of cancer death in the United States. In 2024, CRC is expected to cause more than 53,000 deaths. Sapience Therapeutics, Inc.’s first-in-class β-catenin antagonist, ST316, selectively targets the Wnt pathway, which drives more than 80% of CRCs. We are pleased to announce that we have begun enrolling CRC patients in a Phase 2 Dose Expansion Study across lines of treatment in combination with standard of care. Learn more about the ST316 study here: https://lnkd.in/gpuJBTrn     #FightColorectalCancer #ColorectalCancer

With a favorable safety and tolerability profile and robust pre-clinical data, Sapience Therapeutics, Inc. is committed to maximizing the potential of ST316 in colorectal cancer in various therapeutic combinations across multiple lines of treatment. We are excited to have enrolled the first patient in the Phase 2 expansion study and look forward to its continued recruitment. Click here to learn more: https://lnkd.in/gyqWuTMx #Colorectalcancer #ClinicalTrials #Oncology #DrugDevelopment

#BreakingNews: The first patient has been enrolled in our Phase 2 expansion study evaluating ST316, our first-in-class antagonist of β-catenin (NCT05848739). ST316 selectively shuts down the Wnt/β-catenin signaling pathway in tumor cells but not in normal cells, allowing for anti-cancer activity without the toxicity related to broad inhibition of this pathway. The Wnt/β-catenin signaling pathway is one of the most active pathways in several cancers and drives more than 80% of colorectal cancers – the first indication to be assessed in our Phase 2 expansion study. Click here to learn more: https://lnkd.in/gyqWuTMx #Colorectalcancer #ClinicalTrials #Oncology #DrugDevelopment

Next week, we are looking forward to participating in the UBS Biotechnology Private Company Virtual Symposium and engaging with investors in one-on-one meetings. More info here: https://lnkd.in/gmxfGj5a #UBSBiotechSymposium #Biotech #DrugDiscovery #UBSBiotechSymposium

Being a CMO is a pivotal role that demands leadership, strategic vision, and adaptability. Abi Vainstein-Haras, MD, our CMO, sat down with Chief Medical Officer 360º to discuss the evolving responsibilities of this position. In this interview, Dr. Vainstein-Haras shares valuable tips for new CMOs on transitioning from academia to industry, leading clinical trials, and making an impactful first impression. Read more here: https://lnkd.in/gwS3Mdpv #CMO #ChiefMedicalOfficer #Biotech